Island Pharmaceuticals starts USAMRIID pre-trial surgeries
Key points
- Island Pharmaceuticals commenced scheduled surgical preparations on 22 non-human primates for its Galidesivir Marburg virus dose optimisation study.
- The announcement moved the company's share price to $0.30 on the Australian Securities Exchange.
- The study aims to establish an optimal dosing regimen to support future pivotal efficacy trials under the US FDA Animal Rule pathway.
Island Pharmaceuticals (ASX:ILA) has commenced scheduled surgical preparations for 22 non-human primates at the United States Army Medical Research Institute of Infectious Diseases.
The surgical preparations follow the successful completion of screening activities announced on Oct. 19.
CEO and Managing Director, Dr David Foster said, "The commencement of surgical preparations at USAMRIID is another important milestone for Island and demonstrates the continued progress being made towards the start of our Galidesivir dose optimisation study."
The procedures involve 20 active non-human primates and two reserves to evaluate Galidesivir against the Angola strain of the Marburg virus.
Following the announcement, the Island Pharmaceuticals share price was unchanged at $0.30.
Island Pharmaceuticals stated that Galidesivir dosing remains on track to begin in early December 2026 after the subjects complete a recovery period.
The data collected from the study will support the company's ongoing drug development programme under the US Food and Drug Administration Animal Rule regulatory pathway.
